Sanofi-Aventis Licenses CureDM's Early-Stage Diabetes Compound To Bolster Pipeline
This article was originally published in The Pink Sheet Daily
Executive Summary
Privately-held CureDM could receive up to $335 million in payments, plus sales royalties, from Sanofi-Aventis.